agents in our country’s market for the management of the storage symptoms and investigated whether this special tool im- prove taking drug history from the pa- tients with refractory storage symptoms in this prospective study. Material and Methods: The patients who presented with refractory OAB symp- toms to our outpatient clinic were asked about previous drug history and the pa- tients who could not give information on previous drug history were enrolled into this study. Then, the drug control visual (DCV) were showed to these patients. The tool did not include the form of des- mopressin nasal application. Both conven- tional method of taking history and DCV method was compared statistically with McNemar test. Results: A total of 22 patients (5 female, 17 male) were studied (mean age 28, range 20-74). The characteristics of pa- tients and findings were presented in the table. Conventional history taking method yielded adequately 44.4% of drugs used previously, while DCV provided 100% of drugs used previously (p0.001). Conclusions: Drug control visual can provide adequate drug history in patients who presented with refractory storage symptoms and could not give information on previous drug therapy. UP-03.197 Early Clinical Outcome of Fesoterodine 4 Mg Treatment on 304 Patients with Overactive Bladder Choi WS 1 , Song SH 2 , Ha SB 2 , Cho SY 3 , Lee SB 3 , Jeong H 3 , Son H 3 1 Depts. of Urology, Yanggu Health Center, Yanggu, 2 Seoul National University Hospital, Seoul, 3 Seoul National University Boramae Hospital, Seoul, South Korea Introduction and Objective: Fesoterod- ine is one of the newest antimuscarinic agents, and its clinical efficacy in treating overactive bladder (OAB) has been ap- proved throughout several clinical studies. However, there are a few data available regarding clinical efficacy in Asian popula- tion. Here we report the short-term effi- cacy and complications of 304 overactive bladder patients after fesoterodine treat- ment in Korea. Materials and Methods: This study pro- tocol was reviewed and approved by the Institutional Review Board (IRB) at Seoul National University Boramae Hospital. We retrospectively analyzed 304 overactive bladder patients with fesoterodine 4mg during the last 30 months. We asked pa- tients to complete questionnaires about treatment related efficacy and side effects. Answers to questions about satisfactory results were detailed as ‘satisfied’, ‘no change’, and ‘dissatisfied’. Results: Total study population was con- sisted of 170 males and 134 females. Mean age was 66 years old. Patients with diabetes, hypertension, and cerebrovascu- lar accidents were 21, 41, and 3%, respec- tively. Mean prostatic volume was 31.2 cc in male subjects. 19% of them had been performed prostatic surgery. Most of the male subjects had been treated with tolt- erodine 2mg. Initial fesoterodine dosage was 4mg once daily. There were 274 pa- tients (90.1%) who completed this study protocol and their mean follow-up period was about 12.4 weeks. Patients who re- ported ‘satisfied’, ‘no change’, and ‘dissat- isfied’, were 59, 16, and 15% of the total study population. When we classified sub- jects into 3 different groups: ‘prescription change from tolterodine without dissatis- faction nor side effects’, ‘new cases’, and ‘prescription change from tolterodine due to dissatisfaction or side effects’, the ratio of ‘satisfied’ patients after fesoterodine medication were 74, 66, and 46%, respec- tively. Side effects were voiding difficulty (6.2%), dry mouth (3.2%), and constipa- tion (0.9%). This low frequency of adverse events is unusual and is probably because the question regarding side effects were open question. Conclusions: The results of this study showed a favorable efficacy of fesoterod- ine. Especially, patients previously treated with tolterodine showed the highest rate of satisfaction after medication. Additional studies with longer follow-up period are warranted. UP-03.198 The GnRH-Receptor Antagonist Degarelix Reduces Urodynamic Signs of Detrusor Overactivity in Awake Female Rats Gandaglia G 1 , Benigni F 1 , La Croce G 1 , Moschini M 1 , Strittmatter F 2 , Colli E 3 , Andersson K 4 , Rigatti P 1 , Montorsi F 1 , Hedlund P 1,5,6 1 Urology Research Institute, San Raffaele University, Milan, Italy, 2 Dept. of Urology, University of Munich, Munich, Germany, 3 Ferring Pharmaceuticals, Copenhagen, Denmark, 4 Dept. of Regenerative Medicine, Wake Forest, Winston-Salem, USA, 5 Dept. of Clinical and Experimental Pharmacology, Lund, Sweden, 6 Dept. of Clinical Pharmacology, Linköping, Sweden Introduction and Objective: The aim of our study was to assess the effect of de- garelix, a long-acting GnRH receptor an- tagonist, on bladder function and experi- mental detrusor overactivity (DO) in female rats. Materials and Methods: Forty-two rats were given subcutaneous degarelix (30 or 300 g/kg) or vehicle. Bladder function and response to intravescical (ives) PGE 2 were studied during awake cystometry. Detrusor were processed for functional organ-bath studies, Western Blot and im- munohistochemistry. Plasma LH concen- trations were determined (ELISA). Results: Baseline micturition interval (MI), micturition volume (MV), and blad- der capacity (BC) were similar for degare- lix-treated rats and vehicle. Rats treated with 30g/kg (but not 300g/kg) degare- lix had lower residual volumes (RV) than controls. Basal pressure (BP) and maxi- UP-03.196, Table 1. Patients characteristics and results Characteristics Missing/ false recall (8) Not recalling(14) Sex Female 5 2 3 Male 17 6 11 Education status Literate 2 1 1 Primary school 8 3 5 Secondary school 6 2 4 High school 4 2 2 University 2 0 2 Diagnosis Enuresis nocturna 12 7 5 OAB 10 1 9 Drug use Single 7 0 7 Multiple15 8 7 UNMODERATED POSTER SESSIONS S410 UROLOGY 78 (Supplement 3A), September 2011